Prof. Xiongjun Ye 叶雄俊
Chief Physician, Professor
Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Robotic and laparoscopic surgery for urologic tumors and stones. Expertise includes nephron-sparing surgery for complex kidney tumors, radical cystectomy with orthotopic neobladder, and nerve-sparing radical prostatectomy.
Dr. Ye holds an MD and PhD from Peking University, trained under Academician Guo Yinglu. Formerly at Peking University People’s Hospital, Dr. Ye joined the Cancer Hospital, Chinese Academy of Medical Sciences in February 2022. Completed fellowships at Mayo Clinic and UCSF. Certified da Vinci robotic surgeon.
Professional roles
- Member, Chinese Medical Association (CMA)
- Member, Robotics Group of CMA Urology Branch
- Member, Kidney Cancer/Urothelial Carcinoma Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Youth Committee of Urology, Chinese Research Hospital Association
Name order: in Chinese the family name comes first (Ye Xiongjun). Papers usually list the name as Xiongjun Ye or Ye X.
Selected publications
18 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2026 (senior author): Liquid biopsy in bladder cancer: towards precision oncology. PubMed 42870280
- Geroscience, 2026 (senior author): Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study. PubMed 40931290
- Discov Oncol, 2025 (senior author): Metabolomic Understanding of variable risk factors for kidney cancer: a two-sample Mendelian randomization study. PubMed 40719976
- Sci Rep, 2025 (senior author): The impact of radiotherapy on the prognosis of metastatic clear cell renal cell carcinoma after surgery. PubMed 40348825
- Adv Healthc Mater, 2024 (senior author): Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma. PubMed 39396375
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion